|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM265 |
Gene summary for TMEM265 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM265 | Gene ID | 100862671 |
| Gene name | transmembrane protein 265 | |
| Gene Alias | IFITMD8 | |
| Cytomap | 16p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A087WTH1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100862671 | TMEM265 | sample1 | Human | Cervix | CC | 1.19e-15 | 5.08e-01 | 0.0959 |
| 100862671 | TMEM265 | sample3 | Human | Cervix | CC | 1.07e-42 | 6.31e-01 | 0.1387 |
| 100862671 | TMEM265 | H2 | Human | Cervix | HSIL_HPV | 1.18e-15 | 3.58e-01 | 0.0632 |
| 100862671 | TMEM265 | T1 | Human | Cervix | CC | 5.64e-26 | 4.96e-01 | 0.0918 |
| 100862671 | TMEM265 | T3 | Human | Cervix | CC | 5.86e-41 | 6.44e-01 | 0.1389 |
| 100862671 | TMEM265 | LZE2D | Human | Esophagus | HGIN | 3.64e-03 | 3.22e-01 | 0.0642 |
| 100862671 | TMEM265 | LZE3D | Human | Esophagus | HGIN | 3.66e-03 | 9.26e-01 | 0.0668 |
| 100862671 | TMEM265 | LZE4T | Human | Esophagus | ESCC | 1.25e-18 | 5.15e-01 | 0.0811 |
| 100862671 | TMEM265 | LZE5T | Human | Esophagus | ESCC | 1.28e-07 | 4.41e-01 | 0.0514 |
| 100862671 | TMEM265 | LZE7T | Human | Esophagus | ESCC | 4.33e-11 | 5.50e-01 | 0.0667 |
| 100862671 | TMEM265 | LZE8T | Human | Esophagus | ESCC | 5.45e-16 | 4.71e-01 | 0.067 |
| 100862671 | TMEM265 | LZE20T | Human | Esophagus | ESCC | 8.74e-18 | 6.18e-01 | 0.0662 |
| 100862671 | TMEM265 | LZE22T | Human | Esophagus | ESCC | 4.24e-14 | 7.57e-01 | 0.068 |
| 100862671 | TMEM265 | LZE24T | Human | Esophagus | ESCC | 3.76e-31 | 1.08e+00 | 0.0596 |
| 100862671 | TMEM265 | LZE21T | Human | Esophagus | ESCC | 1.16e-05 | 3.87e-01 | 0.0655 |
| 100862671 | TMEM265 | LZE6T | Human | Esophagus | ESCC | 1.62e-02 | 1.88e-01 | 0.0845 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM265 | SNV | Missense_Mutation | novel | c.158N>T | p.Ala53Val | p.A53V | A0A087WTH1 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-ZJ-A8QO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM265 | SNV | Missense_Mutation | novel | c.262N>T | p.Ala88Ser | p.A88S | A0A087WTH1 | protein_coding | tolerated(0.44) | benign(0.021) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM265 | SNV | Missense_Mutation | novel | c.313N>A | p.Ala105Thr | p.A105T | A0A087WTH1 | protein_coding | tolerated(0.29) | benign(0.059) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| TMEM265 | SNV | Missense_Mutation | novel | c.221N>T | p.Arg74Leu | p.R74L | A0A087WTH1 | protein_coding | deleterious(0.02) | benign(0.29) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| TMEM265 | SNV | Missense_Mutation | rs777559722 | c.86G>A | p.Arg29His | p.R29H | A0A087WTH1 | protein_coding | deleterious_low_confidence(0) | benign(0.013) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |